• Fine Foods completed the acquisition of 100% of Sofar from Alfasigma, closing a deal first disclosed on April 17, 2026.
• Consideration was EUR 23.4 million, paid in cash using bank financing; the price was based on a EUR 27 million enterprise value.
• The purchase price reflected Sofar’s net financial position, intragroup settlements, and other agreed contractual adjustments.
• The deal adds liquid and semi-solid drug-form manufacturing capabilities not previously in Fine Foods’ industrial footprint.
• Alfasigma retains ownership of products made at the Trezzano Rosa site under a long-term contract manufacturing agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fine Foods & Pharmaceuticals NTM S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20094_168726_2026_oneinfo.pdf), on June 12, 2026, and is solely responsible for the information contained therein.